Código QR (código de barras bidimensional)

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Background: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, the active me...

ver descrição completa

Na minha lista:
Principais autores: Emanuele Perrone, Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra, Luca Zammataro, Aranzazu Manzano, Paola Manara, Anna Bianchi, Natalia Buza, Joan Tymon-Rosario, Gary Altwerger, Chanhee Han, Gulden Menderes, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Pei Hui, Peter E. Schwartz, Giovanni Scambia, Alessandro D. Santin
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020-02-01
coleção:Frontiers in Oncology
Assuntos:
sacituzumab govitecan
ovarian carcinoma
antibody drug conjugate (ADC)
Trop-2
target therapy
Acesso em linha:https://www.frontiersin.org/article/10.3389/fonc.2020.00118/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados